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ABSTRACT 
MACRONUTRIENTS AND THE RISK OF PREMENSTRUAL SYNDROME 
 
MAY 2016 
 
SERENA C. HOUGHTON, B.S., UNIVERSITY OF MARY WASHINGTON 
 
M.P.H., EASTERN VIRGINIA MEDICAL SCHOOL 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Dr. Elizabeth R. Bertone-Johnson 
 
 
Premenstrual syndrome (PMS) affects 8-20% of reproductive-aged 
women, impacting work, family, and social interactions.  Limitations in available 
PMS treatments, including side effects and limited medication efficacy, indicate 
the need for improved prevention.  Modifiable risk factors for prevention of PMS 
include dietary factors.  Several micronutrients have been identified as risk 
factors, but there has been little evaluation of macronutrients.  Thus, the research 
aim was to examine prospectively whether macronutrient consumption was 
associated with PMS development among a subset of women enrolled in the 
Nurses’ Health Study II cohort.    
Chapter 1 evaluates the association of fat intake and PMS risk.  Among 
3,638 women, total fat intake was not associated with PMS risk, but stearic acid 
was associated with a 25% decrease risk of PMS.  As this was the first study to 
observe this association, the finding needs to be replicated.    
Chapter 2 assesses intake of carbohydrates and PMS risk.  Overall, 
carbohydrate intake was not associated with PMS risk but maltose was 
 vi 
associated with a 45% increased risk of PMS.  Again, this is the first study to 
find this and replication is needed.   
Chapter 3 evaluates intake of protein and PMS risk.  Protein intake was 
not associated with PMS risk.  Additionally, substitution of macronutrients for 
each other did not suggest that any macronutrient was importantly associated 
with PMS risk.   
In conclusion, macronutrient intake was not associated with risk of 
developing PMS after controlling for micronutrient intake and other potential 
confounders.  Micronutrients may play a more important role in PMS 
development than macronutrient intake.   
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CHAPTER 1 
DIETARY FAT INTAKE AND THE RISK OF PREMENSTRUAL SYNDROME 
Abstract 
Approximately 8-20% of reproductive aged women experience premenstrual 
syndrome (PMS), a cyclical late luteal phase disorder of the menstrual cycle whereby the 
daily functioning of women is affected by emotional and physical symptoms.  Women 
with PMS are encouraged to reduce fat intake as a way to reduce premenstrual 
symptoms, though research supporting this recommendation is limited, and its role in the 
development of PMS is unclear.  The purpose of this study was to examine the 
association between intake of specific dietary fatty acids and the development of PMS 
among a subset of participants in the prospective Nurses’ Health Study II cohort.  We 
compared 1,257 women reporting clinical diagnosis of premenstrual syndrome, 
confirmed by premenstrual symptom questionnaire and 2,463 matched controls with no 
or minimal premenstrual symptoms.  Intakes of total fat, fat subtypes, and individual fatty 
acids were assessed quadrennially via food frequency questionnaires.  After adjustment 
for age, body mass index, smoking, calcium, and other factors, intakes of total fat, 
monounsaturated, polyunsaturated, and trans fat measured 2-4 years before the reference 
year were not associated with PMS.  High saturated fat intake was associated with lower 
risk of PMS (relative risk [RR] quintile 5 [median = 28.1 g/day] versus quintile 1 
[median = 15.1 g/day] = 0.75; 95% confidence interval [CI] = 0.58-0.97; p for trend = 
0.04).  This association was largely driven by stearic acid intake, with women in the 
highest quintile (median = 7.4 g/day) having a RR of 0.75 versus those with the lowest 
intake (median = 3.7 g/day) (95% CI = 0.57-0.98; p for trend = 0.03).  Individual 
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polyunsaturated and monounsaturated fats, including omega-3 fatty acids, were not 
associated with risk.  Overall, fat intake was not associated with higher risk of PMS.  
High intake of stearic acid may be associated with a lower risk of developing 
premenstrual syndrome.  Additional prospective research is needed to confirm this 
finding.   
Introduction 
Premenstrual syndrome (PMS) is a cyclical late luteal phase disorder of the 
menstrual cycle whereby the daily functioning of women is affected by emotional and 
physical symptoms.  It is estimated that approximately 8-20% of reproductive aged 
women meet clinical diagnostic criteria for PMS.1,2   Several treatment options exist (e.g., 
oral contraceptives, gonadotropin-releasing hormone agonists, antidepressants); however, 
there may be side effects and efficacy is relatively low.3  Thus, it is important to identify 
modifiable risk factors to prevent the initial development of premenstrual syndrome, 
particularly those that are easy to implement, such as dietary recommendations.   
The American Congress of Obstetricians and Gynecologists (ACOG) 
recommends reducing fat intake to treat PMS.4  However, evidence supporting these 
recommendations is limited, and it is unclear whether they apply to the prevention of 
PMS development.5 A small number of retrospective studies have reported inconsistent 
relationships between premenstrual symptoms with consumption of fats.6,7  Among 
retrospective studies, because of issues related to establishing temporality, it is unknown 
whether increased fat and fatty acid intake precedes the development of PMS.  
Additionally, little attention has been given to specific types of fat, with most studies 
evaluating either total fat6,7 or evening primrose oil.8  To our knowledge, no previous 
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study has prospectively evaluated whether total fat, fat subtypes, or individual fatty acid 
intake is associated with risk of developing PMS. 
Therefore, we evaluated the relation between intake of specific dietary fatty acids 
and the development of premenstrual syndrome in the Nurses’ Health Study II (NHS2) 
PMS Sub-Study, a case-control study nested within the prospective NHS2. 
Methods 
Study Population 
The NHS2 is a large prospective cohort of 116,686 US female registered nurses, 
aged 25-42 years in 1989, that has assessed demographics, health-related behaviors, diet, 
and medical history biennially and diet quadrennially for over 25 years.9  Response rates 
have been ≥89% for all questionnaire cycles.  The original NHS2 study protocol was 
approved by the Intuitional Review Board at Brigham and Women’s Hospital.   
Classification of PMS cases and controls 
The NHS2 PMS Sub-Study has been described previously.9,10  Briefly, we 
identified all NHS2 members who had not reported diagnosis of PMS by a clinician in 
either 1989 or 1991 and thus were at risk of developing PMS.  Premenopausal women 
reporting a new clinician-made diagnosis of PMS during the follow-up period in 1991-
2005 (1993-2007 questionnaires) were selected as potential cases (n=4,108) with the 
diagnosis year used as their reference year.  Potential controls were randomly selected 
from women that did not report a diagnosis of PMS from 1991-2005 (3,248) and were 
randomly assigned a reference year (1991-2005), and then were frequency matched to 
cases on age and reference years.  Women who had reported a history of cancer (other 
than non-melanoma skin cancer), endometriosis, extremely irregular menstrual cycles, 
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infertility, hysterectomy, or menopause prior to their assigned reference year were 
excluded.  Additionally, because of our interest in diet, those with implausible caloric 
intakes (i.e., those below 500 calories and above 3,500 calories) were also excluded. 
All potential cases and controls were sent a modified version of the Calendar of 
Premenstrual Experiences (COPE) questionnaire10,11 that assessed the occurrence of 26 
physical and affective symptoms in the two-years prior to their specific reference year, 
the timing of symptoms, and the impact of symptoms on several domains of daily 
functioning.   
There were 1,257 women that met clinical diagnostic guidelines for PMS.  
Specifically, the cases had: 1) ≥1 physical and ≥1 affective menstrual symptoms; 2) 
overall symptom severity of “moderate” or “severe” OR “moderate” or “severe” effect of 
symptoms on at least one life activity or relationship; 3) symptoms begin ≤14 days prior 
to start of menses; 4) symptoms end ≤4 days after start of menses; and 5) symptoms not 
present in week after menses ended.9   
Women that had no or minimal symptoms that did not impact daily function 
domains were controls (n=2,463).  Specifically they had: 1) confirmed no PMS 
diagnosis; 2) either no menstrual symptoms OR an overall symptom severity of 
“minimal” or “mild”; and 3) either “no effect” or “mild” effect of symptoms on all life 
activities and relationship domains.9     
Participants who did not meet these definitions were excluded from further 
analysis, allowing for a comparison of women at the two extreme ends of the spectrum of 
premenstrual symptom experience in order to reduce the likelihood of misclassification 
of cases as controls and vice-versa.   
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Assessment of fat intake and other factors 
In the NHS2, a 131-item semi-quantitative food frequency questionnaire (FFQ) 
was first given in 1991 and then every four years thereafter.  We used food intake 
information reported on the FFQ to assess the intake of total fat, saturated fat, 
monounsaturated fat, polyunsaturated fat, trans fat, dairy fat, animal fat, vegetable fat, 
total omega-3, total omega-6, the ratio of omega-6 to omega-3, and specific fatty acids 
including stearic acid, oleic acid, arachidonic acid, linoleic acid, conjugated linoleic acid, 
linolenic acid, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA).  The FFQ 
included food high in fat such as red meat, chicken with skin, bacon, processed meats, 
fish, eggs, butter, margarine, whole milk, cheese, ice cream, French fries, potato chips, 
peanut butter, and nuts.  Additionally, participants were asked about the types of fat used 
for frying and baking and whether fish oil or cod liver oil supplements are used.  
Participants indicated the frequency to which they consumed a specific portion size of 
each food item, with a 9-option range from “never or less than once per month” to “6 or 
more times per day.”  To calculate each participant’s dietary fat intakes, the portion size 
of each food item was multiplied by the indicated frequency of consumption and summed 
across all foods and fat content.  Dairy fat is a subset of animal fat (animal fat also 
includes dairy fats), which includes all fat from the foods in the “Dairy Foods” section on 
the FFQ except for margarine and non-dairy whitener and fat from the dairy products 
used as ingredients in other FFQ items.  Nutrient intakes were adjusted for total energy 
using the residual method.12    
The validity of similar FFQs have been evaluated previously in the Nurses’ 
Health Study.  The energy adjusted correlation between intakes reported by FFQ and 
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mean intake measured via two 1-week diet records was 0.51, 0.59, 0.41, and 0.51 for total 
fat, saturated fat, polyunsaturated fat, and monounsaturated fat, respectively.12    
Adjusted intakes from food and supplement sources at baseline (1991) and the 2-4 
year period prior to each woman’s reference year were evaluated.  Dietary information 
from 3,660 Sub-Study participants was available for analyses of intake at baseline in 
1991 and for 3,638 women for analyses of intake 2-4 years before the reference year.   
Information on other factors potentially associated with PMS and diet were 
collected on the biennial questionnaires and included: age, smoking status, weight, 
pregnancy history, and oral contraceptive use.  Height and menstrual cycle characteristics 
were assessed on the 1989 questionnaire.  History of depression and antidepressant use 
were assessed on the menstrual cycle questionnaire.  Childhood trauma was assessed in 
2001 on a separate questionnaire.13  Lastly, other nutrients such as B-vitamins, iron, and 
calcium were assessed by FFQ and calculated using similar methods as fat intake. 
Statistical analysis 
Age-adjusted baseline characteristics of PMS cases and controls were compared 
using generalized linear modeling.  We used unconditional logistic regression models to 
estimate relative risks (RR) of PMS for women across quintiles of fat intake and 
calculated 95% confidence intervals (CI) comparing the risk of PMS in each of the four 
highest quintiles compared to the lowest quintile adjusting for age.  Multivariable logistic 
regression models additionally adjusted for reference year, age, age at menarche,  current 
body mass index (BMI; weight [kg]/height [m2]), physical activity, oral contraceptives, 
parity [pregnancies lasting ≥6 months], smoking [pack-years], previous use of 
antidepressants, significant childhood trauma, previous diagnosis of depression, total 
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intake of vitamins B6, B1, iron, and calcium.  Primary analyses used intake at 2-4 years 
prior to diagnosis; additional models were run using the intake at baseline to assess the 
possibility of latent effects.  Additional analyses also adjusted subtypes of fat for the 
effect of other subtypes (e.g., saturated fat was adjusted for monounsaturated, 
polyunsaturated, and trans fat) and each source of fat was adjusted for the other sources 
(e.g., dairy fat was also adjusted for vegetable and animal fat).  The Mantel extension test 
for trend was used to examine the presence of linear trend across quintiles modeling the 
median of each quintile as a continuous variable.   
We further assessed whether the relationship of dietary fat and PMS varied by age 
at reference year (<40 versus ≥40 years) and smoking (past/never versus current) via 
stratified analyses.  The multiplicative interaction terms were evaluated using likelihood 
ratio test, where the interaction terms were calculated as the products of a binary 
stratification factor and indicators of the macronutrient quintile.  We also restricted 
analyses to non-oral contraceptive users.    
SAS 9.3 (SAS Institute Inc., Cary, NC, USA) was used for all analyses.  Two-
sided p-values <0.05 were considered statistically significant for all analyses.   
Results 
Baseline characteristics of PMS cases and controls are shown in Table 1.  Cases 
were heavier at baseline and age 18, had a slightly earlier age at menarche, and had 
higher history of oral contraceptive use, smoking, significant childhood trauma, 
depression and antidepressant use.  Additionally, cases on average consumed less vitamin 
D, calcium, and vitamins B6 and B12 than controls.  
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Table 2 presents age-adjusted and multivariate-adjusted RR and 95% CI for types 
of fats consumed 2-4 years prior to the reference year and the risk of developing PMS.  In 
analyses adjusted only for age, total fat, polyunsaturated fat, and monounsaturated fat 
were each positively associated with risk of developing PMS (p for trend <0.05 for all).  
However, after controlling for BMI, smoking, and additional covariates, these positive 
associations were attenuated and no longer significant.  In multivariable adjusted models 
(Model 1), high saturated fats was inversely associated with risk of PMS (RR quintile 5 
versus quintile 1 = 0.75; 95% CI = 0.58-0.97).  When the models additionally adjusted 
for other fats (Model 2), saturated fat estimates were slightly stronger (RR quintile 5 
versus quintile 1 = 0.63; 95% CI = 0.44-0.92).  The estimates for other sub-types of fats 
were largely unchanged and interpretations did not change.   
Table 3 shows results from models assessing risk of PMS related to sources of 
fats.  Intakes of vegetable and dairy fats were unrelated to PMS risk, with estimates for 
all quintiles approximately equal to one.  High animal fat intake was related to a non-
significant lower risk of PMS in age-adjusted (p for trend = 0.53) and multivariable 
adjusted (Model 1) models (p for trend = 0.17).  Additional adjustment for the other 
sources of fat (Model 2) did not affect the interpretations of the estimates.   
Results for models of fatty acid intake and PMS risk are presented in Table 4.  
Stearic acid, a saturated fatty acid, was inversely associated with PMS risk.  Women with 
the highest intake of stearic acid (quintile median = 7.4 g/day) had significant 25% lower 
risk of PMS than women with the lowest intake (quintile median = 3.7 g/day) (95% CI = 
0.57-0.98; p for trend = 0.03).  We did not find intake of other individual fatty acids to be 
associated with risk.  
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Results evaluating fat and fatty acid intake at baseline (data not shown), to assess 
latent effects, were largely similar to those evaluating fat intake at reference year, 
including results for stearic acid.  High intake of stearic acid (quintile median = 7.6 
g/day) had 20% lower risk, albeit non-significant, than those with the lowest intake 
(quintile median = 4.1 g/day; 95% CI = 0.62-1.05; p for trend = 0.12).  However, there 
were a few exceptions.  The omega-3s from marine sources, EPA and DHA, showed 
significant positive associations with PMS, with evidence of linear trend.  In fully 
adjusted models, women with the highest EPA intake at baseline (quintile median = 0.12 
g/day) had 1.32 times the risk of PMS as those with the lowest (quintile median = 0.01 
g/day; 95% CI = 0.99-1.75; p for trend = 0.009).  Women with high DHA intake (quintile 
median = 0.26 g/day) had 1.49 times the risk of PMS as those with the lowest intake 
(quintile median = 0.05 g/day; 95% CI = 1.14-1.94; p for trend = 0.004).  These findings 
were counter to expectation and physiological explanations are unknown.   
As BMI could potentially lie in the casual pathway of an association between fat 
intake and PMS risk and could mediate associations, multivariable analyses were 
repeated without adjusting for BMI in the model and estimates were unchanged.  
Analyses stratified by age and smoking status did not suggest effect modification by any 
of these factors and there were no significant interactions.    
Discussion 
We did not find intake of total fat associated with risk of developing PMS.  High 
intake of saturated fat, specifically stearic acid, was significantly associated with lower 
risk.  Other individual fatty acids, including omega-3 fatty acids, were not consistently 
associated with risk. 
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Few studies have comprehensively assessed how fat and fatty acid intake may be 
related to PMS.  To date no studies of PMS have utilized prospectively assessed fat or 
fatty acid intake other than supplement trials.  Prior research of the relation between fat 
intake and PMS has been limited to consideration of symptom presence and/or severity, 
rather than risk of developing PMS.  Both Nagata et al. (2004) and Gold et al. (2007) 
assessed total fat intake with premenstrual symptoms using cross-sectional study 
designs.6,7    
Nagata et al. examined whether total fat and fat subtypes were associated with the 
severity of premenstrual symptoms among 189 female Japanese students aged 19-34 
years.6  Total fat, saturated fat, and monounsaturated fat were associated with higher 
overall symptom severity in the premenstrual phase as well as for pain severity 
specifically.   
In contrast, in the Study of Women’s Health Across the Nation (SWAN), Gold et 
al. found total fat intake to be associated with lower cravings/bloating symptoms in older 
premenopausal women, but was unrelated to the other symptoms assessed, including 
back pain/cramps, breast pain, or headaches.7  
The inconsistencies in the findings among these studies may be due to the cross-
sectional study design.  With the cross-sectional design assessing symptoms, temporality 
cannot be established and it becomes unclear whether the women are consuming foods 
with higher fat sources due to cravings in order to alleviate symptoms or whether higher 
intakes of fat are physiologically involved in the development of premenstrual symptoms.  
Secondly, the SWAN cohort is an older population (42-52 years) and thus may be 
capturing perimenopausal symptoms.   
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Saturated fat was inversely associated with the risk of developing PMS in our 
study and appeared to be largely driven by stearic acid.  The inclusion of stearic acid in 
the model for saturated fat attenuated the results and the estimates for saturated fat 
became null (RR quintile 5 versus quintile 1 = 1.07; 95% CI = 0.63-1.82).  Stearic acid 
associations with PMS risk were similar after adjustment for saturated fat; however, due 
to wider confidence intervals the associations were no longer significant (RR quintile 5 
versus quintile 1 = 0.68; 95% CI = 0.40-1.18).  Laboratory and clinical evidence suggests 
that stearic acid may be physiologically different from other saturated fats.14-17  Stearic 
acid appears to have a neutral effect or may even lower cholesterol levels as opposed to 
increasing lipid levels,14,15 and may potentially lower risk of breast cancer 16 and 
cardiovascular disease.15  A common source of stearic acid is cocoa butter, which is a 
primary component of chocolate.17  Many women report chocolate cravings 
premenstrually and may increase chocolate intake to improve symptoms.18  In post hoc 
analyses, we evaluated whether chocolate intake may explain the association between 
stearic acid and PMS risk.  When we adjusted for chocolate intake the relationship was 
slightly attenuated (RR quintile 5 versus quintile 1 = 0.80; 95% CI = 0.60-1.07).  As no 
other studies have evaluated the relationship between stearic acid and PMS, additional 
studies specifically evaluating whether stearic acid intake may reduce PMS risk or be 
beneficial in treating premenstrual symptoms are warranted.   
Several clinical trials have tested the efficacy of treating premenstrual symptoms 
with fatty acid supplements.  Clinical trials looking at supplements of omega-3s, a 
mixture of polyunsaturated fatty acids (GLA, oleic, linoleic, other polyunsaturated fats, 
and vitamin E),19 and krill oil (high in omega-3)20 have suggested that these supplements 
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can alleviate premenstrual symptoms.  Doses and durations of supplementation varied; 
Sohrabi used 2g of omega-3 for one full cycle and then during the late luteal phase for 
two cycles,21 Filho used 1-2g of the polyunsaturated fatty acids for six months,19 and 
Sampalis compared 2g of krill oil to 2g fish oil for one full cycle then during the late 
luteal phase for two more cycles.20  These doses are comparable to our highest quintile of 
intake for omega-3.  However, our study did not find an association with risk of PMS for 
polyunsaturated fat, oleic, linoleic, or omega-3 fatty acids.  Additionally, there was very 
little supplement use of fish oil or cod liver oil in our study.   
We were unable to use prospective symptom charting to assess incident PMS in 
our large, ongoing prospective cohort.  However, we used strict criteria to classify PMS 
cases and controls, excluding women in the middle of the symptom spectrum and thus 
reducing the likelihood of misclassification of cases as controls and vice-versa.  Women 
that experience severe symptoms each month and women that experience no symptoms 
or very minimal symptoms are likely to accurately recall symptom experience and 
unlikely to be misclassified between the two groups.9    Additionally, in a previous 
validation study our method of classifying PMS cases was found to be comparable to 
methods additionally using report of prospective symptom charting as part of clinical 
diagnosis.10   
Participants may either over-report or under-report their intake of foods 
containing fats or fatty acids either unintentionally or purposefully due to beliefs about 
what they should be eating.  This misclassification would attenuate our findings, though 
it is less likely, as previous validation studies have found fat intakes from FFQ data to be 
reasonably well correlated with diet record (r>0.41).12  Secondly, several previous studies 
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within the NHS2 suggest that FFQs are sensitive enough to detect associations between 
fats and outcomes such as endometriosis or cardiovascular disease at similar ranges of 
intake.22,23  Additionally, the range of intake for total fat and subtypes of fat (i.e., 
saturated, monounsaturated, polyunsaturated, and trans fat) within our study was 
comparable to previous observational studies of PMS.6,7   
Overall, we did not find intake of dietary fats to be associated with higher risk of 
PMS, though high intake of stearic acid was associated with a statistically significant 
lower risk of PMS.  As this is the first study to suggest this association, additional 
prospective studies are needed to further evaluate whether stearic acid may reduce risk of 
developing PMS or improve existing symptoms.    
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Table 1.1. Age-standardized characteristics of premenstrual syndrome cases and 
controls at baseline (n=3,660): NHS2 PMS Sub-Study, 1991-2005. 
  Cases (n=1234) 
Controls 
(n=2426)   
Characteristics1 Mean (SD) Mean (SD) p-value3 
Age, years 33.9 (4.2) 34.5 (3.9) <0.0001 
Body mass index (kg/m2)    
At baseline (1991) 24.6 (5.2) 23.7 (4.7) <0.0001 
At age 18 21.4 (3.3) 21.1 (3.1) 0.02 
Age at menarche, years 12.4 (1.4) 12.5 (1.4) 0.05 
Age at first birth, years2 25.9 (3.9) 26.1 (3.7) 0.10 
Number of full-term pregnancies (≥6 months) 1.6 (1.2) 1.6 (1.2) 0.36 
Physical activity, METS/week 22.9 (60.2) 23.6 (55.6) 0.74 
Pack-years of cigarette smoking 8.3 (64.7) 4.8 (50.2) 0.09 
Alcohol intake, g/day 3.1 (6.5) 3.1 (5.7) 0.99 
Total calorie intake, kcal/day 1826 (537) 1813 (520) 0.62 
Vitamin D intake food sources, IU/day4 255 (119) 266 (123) 0.01 
Total vitamin B6 intake, mg/day4 5.8 (15.6) 8.6 (26.3) <0.0001 
Total vitamin B12 intake, mg/day4 9.4 (8.5) 10.1 (14.2) 0.04 
Total thiamin intake, mg/day4 3.2 (6.0) 3.6 (8.2) 0.09 
Total riboflavin intake, mg/day4 3.6 (5.7) 4.1 (8.2) 0.07 
Total iron intake, mg/day4 25.8 (24.8) 24.9 (23.3) 0.35 
Total zinc intake, mg/day4 15.7 (10.28) 15.9 (10.7) 0.59 
Total potassium intake, mg/day4 2925 (499) 2897 (501) 0.17 
Total calcium intake, mg/day4 1030 (403) 1063 (421) 0.03 
    
  % % p-value3 
History of tubal ligation 15 16 0.66 
Oral contraceptive use    
Ever 85 77 <0.0001 
Current 12 11 0.33 
Duration > 4 years 43 37 0.001 
Smoking status    
Current 13 7 <0.0001 
Past 27 17 <0.0001 
Previously diagnosed with depression 15 7 <0.0001 
Previously used antidepressant medication 12 5 <0.0001 
History of childhood trauma 18 9 <0.0001 
1All characteristics, except age, standardized to the age distribution of participants in 1991 
2Limited to parous women 
3Calculated using generalized linear model 
4Energy adjusted values 
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Table 1.2. Age-adjusted and multivariable relative risks (RR)1 and 95% confidence 
intervals (CI) for quintiles of dietary fat subtypes 2 to 4 years before diagnosis and 
risk of PMS (n=3,638): NHS2 PMS Sub-Study, 1991-2005. 
 Quintile of fat intake  
  Q1 Q2 Q3 Q4 Q5 p-trend 
Total fat       
Median, g/day 46.4 55.6 62.3 68.2 76.8  
Case: Control Ratio 228:506 256:502 258:509 234:470 246:429  
RR (95% CI)       
Age-adjusted Ref 1.13 1.13 1.11 1.29 0.05 
Model 1 Ref 1.06 (0.84-1.34) 
1.01 
(0.80-1.28) 
0.92 
(0.72-1.18) 
0.95 
(0.73-1.23) 0.44 
Saturated fat        
Median, g/day  15.1 18.9 21.6 24.3 28.1  
Case: Control Ratio 235:440 242:525 249:536 260:472 236:443  
RR (95% CI)       
Age-adjusted Ref 0.85 0.86 1.01 0.98 0.65 
Model 1 Ref 0.81 (0.63-1.02) 
0.78  
(0.61-0.99) 
0.85 
(0.66-1.09) 
0.75 
(0.58-0.97) 0.07 
Model 2 Ref 0.74  (0.56-0.97) 
0.68  
(0.50-0.92) 
0.73  
(0.53-1.02) 
0.63  
(0.44-0.92) 0.04 
Polyunsaturated fat 
Median, g/day 7.8 9.5 10.8 12.2 14.5  
Case: Control Ratio 247:540 245:474 229:484 251:490 250:428  
RR (95% CI)       
Age-adjusted Ref 1.14 1.03 1.15 1.33 0.02 
Model 1 Ref 1.13 (0.90-1.43) 
0.99 
(0.78-1.26) 
1.11  
(0.87-1.40) 
1.14 
(0.89-1.46) 0.36 
Model 2 Ref 1.14  (0.89-1.45) 
1.00  
(0.78-1.29) 
1.12  
(0.86-1.44) 
1.15  
(0.88-1.52) 0.38 
Monounsaturated fat  
Median, g/day 17.0 21.0 23.8 26.4 30.4  
Case: Control Ratio 233:502 251:523 261:505 236:462 241:424  
RR (95% CI)       
Age-adjusted Ref 1.04 1.12 1.12 1.25 0.04 
Model 1 Ref 0.98 (0.77-1.24) 
1.00 
(0.79-1.27) 
0.93 
(0.72-1.19) 
0.97 
(0.74-1.25) 0.70 
Model 2 Ref 1.11  (0.84-1.47) 
1.19  
(0.86-1.64) 
1.12  
(0.77-1.62) 
1.20  
(0.79-1.81) 0.45 
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Table 1.2., Continued. 
 Quintile of fat intake  
  Q1 Q2 Q3 Q4 Q5 p-trend 
Trans fat      
Case: Control Ratio 218:457 242:481 243:498 270:526 249:454  
RR (95% CI)       
Age-adjusted Ref 1.04 1.01 1.06 1.14 0.25 
Model 1 Ref 1.10 (0.86-1.41) 
0.97 
(0.76-1.25) 
0.96 
(0.75-1.23) 
1.03 
(0.79-1.34) 0.83 
Model 2 Ref 1.17  (0.90-1.51) 
1.05  
(0.80-1.38) 
1.04  
(0.78-1.39) 
1.11  
(0.81-1.52) 0.80 
1Model 1 adjusted for age (continuous), reference year (91-92, 93, 94-96, 97-98, 99-00, 01-02, 03-04), age 
at menarche (continuous), current body mass index (≤19.9, 20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.9, ≥30 
kg/m2), physical activity (<3, 3-8, 9-17, 18-26, 27-41, ≥42 METs), oral contraceptives (none, 1-23, 24-71, 
72-119, ≥120 months), parity (nulliparous, 1-2, 3-4, ≥5 pregnancies >6 months), smoking (never, past 1-14, 
past 15-34, past 35+, current 1-14, current 15-34, current 35+ cig/day), previous use of antidepressants 
(never, ever), significant childhood trauma (5, 6-10, 11-15, 16-20, 21-25), previous diagnosis of depression 
(never, ever), and quintiles of total intake for vitamins B6, B1, iron, and calcium at 2 to 4 years before 
reference year 
2Model 2 adjusted for factors included in Model 1 + mutually adjusted for other fat subtypes 
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Table 1.3. Age-adjusted and multivariable relative risks (RR)1 and 95% confidence 
intervals (CI) for quintiles of dietary fat sources 2 to 4 years before reference year 
and risk of PMS (n=3,638): NHS2 PMS Sub-Study, 1991-2005. 
 Quintile of fat intake  
  Q1 Q2 Q3 Q4 Q5 p-trend 
Animal fat       
Median, g/day 21.7 28.9 33.6 38.7 46.9  Case: Control 
Ratio 243:466 228:504 260:524 259:488 232:434  
RR (95% CI)       
Age-adjusted Ref 0.85 0.93 1.00 1.01 0.53 
Model 1 Ref 0.77 (0.61-0.99) 
0.81 
(0.64-1.03) 
0.85 
(0.67-1.08) 
0.78 
(0.61-1.00) 0.14 
Model 2 Ref 0.86  (0.67-1.10) 
0.89  
(0.69-1.14) 
0.88  
(0.68-1.13) 
0.81  
(0.61-1.07) 0.17 
Dairy fat       
Median, g/day 5.9 9.5 12.0 15.1 20.5  Case: Control 
Ratio 192:375 246:456 263:505 263:568 258:512  
RR (95% CI)       
Age-adjusted Ref 1.04 0.98 0.87 0.95 0.33 
Model 1 Ref 1.07 (0.83-1.38) 
1.02 
(0.79-1.33) 
0.89 
(0.69-1.15) 
1.01 
(0.77-1.32) 0.65 
Model 2 Ref 1.10  (0.84-1.43) 
1.16  
(0.88-1.53) 
1.03  
(0.77-1.37) 
1.07  
(0.78-1.45) 0.82 
Vegetable fat        
Median, g/day 18.2 23.3 27.4 31.2 37.9  Case: Control 
Ratio 229:491 246:510 241:491 260:477 246:447  
RR (95% CI)       
Age-adjusted Ref 1.05 1.05 1.20 1.23 0.03 
Model 1 Ref 0.98 (0.77-1.24) 
1.06 
(0.83-1.34) 
1.10 
(0.86-1.40) 
1.05 
(0.82-1.35) 0.49 
Model 2 Ref 1.13  (0.89-1.43) 
1.01  
(0.80-1.29) 
1.04  
(0.82-1.33) 
0.98  
(0.76-1.26) 0.60 
1Model 1 adjusted for reference year, age, age at menarche, current body mass index, physical activity, oral 
contraceptives, parity, smoking, previous use of antidepressants, significant childhood trauma, previous 
diagnosis of depression, total intake of vitamins B6, B1, iron, and calcium at 2 to 4 years before reference 
year 
2Model 2 adjusted for factors included in Model 1 + mutually adjusted for other fat subtypes 
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Table 1.4. Age-adjusted and multivariable relative risks (RR)1 and 95% confidence 
intervals (CI) for quintiles of fatty acids 2 to 4 years before reference year and risk 
of PMS (n=3,638): NHS2 PMS Sub-Study, 1991-2005. 
 Quintile of fat intake  
  Q1 Q2 Q3 Q4 Q5 p-trend 
Stearic acid (18:0)       
Median, g/day 3.7 4.8 5.6 6.3 7.4  
Case: Control Ratio 240:427 231:550 279:527 225:482 247:430  
RR (95% CI)       
Age-adjusted Ref 0.74 0.93 0.82 1.00 0.65 
Model 1 Ref 0.76 0.84 0.70 0.75 0.03 
95% CI2  0.60-0.96 0.66-1.06 0.54-0.90 0.57-0.98  
Oleic acid (18:1)       
Median, g/day 15.7 19.3 21.9 24.4 28.2  
Case: Control Ratio 235:504 243:519 268:509 239:448 237:436  
RR (95% CI)       
Age-adjusted Ref 1.01 1.13 1.16 1.19 0.06 
Model 1 Ref 0.94 1.00 0.98 0.91 0.64 
95% CI2  0.74-1.19 0.79-1.26 0.77-1.27 0.70-1.18  
Linoleic acid (18:2) 
Median, g/day 6.6 8.1 9.3 10.6 12.8  
Case: Control Ratio 248:522 240:486 242:467 240:519 252:422  
RR (95% CI)       
Age-adjusted Ref 1.04 1.09 0.99 1.31 0.04 
Model 1 Ref 1.01 1.06 0.95 1.12 0.53 
95% CI2  0.80-1.29 0.83-1.34 0.75-1.20 0.87-1.43  
Conjugated linoleic acid (c-9,c-12 18:2) 
Median, g/day 57.7 78.2 93.2 108.7 134.8  
Case: Control Ratio 237:430 211:488 261:526 265:502 248:470  
RR (95% CI)       
Age-adjusted Ref 0.77 0.88 0.94 0.92 0.87 
Model 1 Ref 0.75 0.79 0.87 0.80 0.39 
95% CI2  0.58-0.96 0.62-1.01 0.68-1.11 0.62-1.03  
Linolenic acid (18:3) 
Median, g/day 0.72 0.86 0.97 1.09 1.33  
Case: Control Ratio 247:523 241:509 234:440 258:494 242:450  
RR (95% CI)       
Age-adjusted Ref 1.02 1.14 1.15 1.18 0.08 
Model 1 Ref 0.95 1.11 1.12 1.01 0.61 
95% CI2  0.75-1.20 0.87-1.41 0.88-1.41 0.80-1.29  
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Table 1.4., Continued. 
 Quintile of fat intake  
  Q1 Q2 Q3 Q4 Q5 p-trend 
Arachidonic acid (20:4) 
Median, g/day 0.08 0.11 0.14 0.17 0.23  
Case: Control Ratio 239:506 276:555 245:516 226:479 236:360  
RR (95% CI)       
Age-adjusted Ref 1.05 1.02 1.02 1.42 0.004 
Model 1 Ref 0.98 0.95 0.89 1.11 0.59 
95% CI2  0.78-1.24 0.75-1.21 0.70-1.14 0.86-1.43  
EPA (20:5)       
Median, g/day 0.01 0.02 0.04 0.07 0.12  
Case: Control Ratio 235:488 317:651 203:392 257:469 210:416  
RR (95% CI)       
Age-adjusted Ref 1.04 1.09 1.17 1.10 0.31 
Model 1 Ref 0.92 1.14 1.06 1.09 0.27 
95% CI2  0.73-1.16 0.88-1.47 0.83-1.36 0.83-1.44  
DHA (22:6)       
Median, g/day 0.04 0.07 0.10 0.16 0.24  
Case: Control Ratio 257:547 259:510 262:523 225:413 219:423  
RR (95% CI)       
Age-adjusted Ref 1.09 1.09 1.19 1.15 0.20 
Model 1 Ref 1.16 1.19 1.21 1.20 0.24 
95% CI2  0.92-1.46 0.95-1.51 0.94-1.55 0.92-1.57  
Omega-3 (18:3 + 20:5 + 22:5 + 22:6) 
Median, g/day 0.8 1.0 1.1 1.3 1.7  
Case: Control Ratio 269:575 243:454 254:512 237:475 219:400  
RR (95% CI)       
Age-adjusted Ref 1.17 1.10 1.11 1.24 0.11 
Model 1 Ref 1.24 1.13 1.11 1.19 0.35 
95% CI2  0.98-1.56 0.90-1.43 0.88-1.40 0.93-1.52  
Omega-6 (cis-18:2 + 20:4) 
Median, g/day 6.9 8.3 9.5 10.8 13.2  
Case: Control Ratio 232:527 244:475 249:511 236:477 261:426  
RR (95% CI)       
Age-adjusted Ref 1.19 1.12 1.15 1.46 0.002 
Model 1 Ref 1.13 1.05 1.10 1.21 0.18 
95% CI2  0.89-1.43 0.83-1.33 0.86-1.40 0.95-1.55  
Omega-6: Omega-3 
Median, g/day 6.2 7.5 8.3 9.3 11.2  
Case: Control Ratio 211:420 224:477 246:480 285:528 256:501  
RR (95% CI)       
Age-adjusted Ref 0.93 1.01 1.03 0.99 0.81 
Multivariate Ref 0.84 0.94 0.92 0.86 0.44 
95% CI2  0.65-1.08 0.73-1.21 0.72-1.19 0.66-1.12  
1Model 1 adjusted for reference year, age, age at menarche, current body mass index, physical activity, oral 
contraceptives, parity, smoking, previous use of antidepressants, significant childhood trauma, previous 
diagnosis of depression, total intake of vitamins B6, B1, iron, and calcium at 2 to 4 years before reference 
year 
295% CI is for multivariable model 
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CHAPTER 2 
CARBOHYDRATE AND FIBER INTAKE AND THE RISK OF 
PREMENSTRUAL SYNDROME 
Abstract 
Premenstrual syndrome (PMS) is a cyclical late luteal phase disorder of the 
menstrual cycle whereby physical and emotional symptoms impact the daily functioning 
of reproductive aged women.  Up to 20% of reproductive aged women are estimated to 
meet clinical diagnostic guidelines for PMS.  Women with PMS are encouraged to reduce 
sugar intake and increase high-fiber food intake, particularly whole grains, to improve 
symptoms; however, research supporting these recommendations is limited, and its role 
in the development of PMS is unclear.  The purpose of this study was to examine the 
relationship between carbohydrate and fiber intake and the risk of incident PMS among 
participants in the PMS Sub-Study of the prospective Nurses’ Health Study II cohort.  
Incident cases of PMS (n=1,257) were identified by self-reported diagnosis of PMS 
during 14 years of follow-up and validated using a questionnaire based on the Calendar 
of Premenstrual Experience.  Controls (n=2,463) were women who did not report a 
diagnosis of PMS during follow-up and confirmed experiencing no or minimal 
premenstrual symptoms.  Carbohydrate and fiber intake was assessed four times during 
follow-up by food frequency questionnaire.  Unconditional multivariable logistic 
regression was used to estimate relative risks (RR) and 95% confidence intervals (CI).  
Total carbohydrate intake 2-4 years prior to reference year was not associated with PMS 
development (RR comparing quintile 5 to quintile 1 = 0.99; 95% CI = 0.74-1.33).  
Additionally, intakes of specific types of carbohydrates or fibers were not associated with 
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PMS development, with the exception of maltose.  After adjustment for body mass index, 
smoking, and other factors, women with the highest maltose intake (median = 3.0g/day) 
had an RR of 1.45 (95% CI = 1.11-1.89) compared to those with the lowest intake 
(median = 1.2g/day).  Overall, carbohydrate and fiber consumption was not associated 
with risk of developing premenstrual syndrome.  As this is among the first studies to 
suggest that maltose may be associated with PMS risk, this finding requires replication in 
further studies.    
Introduction 
Up to 20% of reproductive aged women meet clinical diagnostic criteria for 
premenstrual syndrome (PMS),1,2 a cyclical disorder characterized by physical and 
emotional symptoms occurring during the late luteal phase of the menstrual cycle and 
abating within a few days following the onset of menses.  While the etiology of PMS is 
still largely unknown, an interaction between hormonal, neural, genetic, psychosocial, 
and dietary factors likely contributes.24   
Because of the limited efficacy of pharmaceutical treatments for PMS, there is a 
need for identifying preventive and modifiable risk factors such as diet.  Both the 
Association of Reproductive Health Professionals and the American Congress of 
Gynecology and Obstetrics suggest that women with PMS consume frequent small 
portions of complex carbohydrates, which are high in fiber, and reduce intake of sugar to 
improve symptom severity.4,25  However, these recommendations are based on limited 
empirical evidence.5  A small number of retrospective studies have reported inconsistent 
relationships between premenstrual symptoms with consumption of carbohydrates.6,26,27  
Among retrospective studies, temporality is a concern and thus it is unknown whether 
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increased carbohydrate and sugar intake or lower complex carbohydrates and fiber intake 
precedes the development of PMS.  To our knowledge, no previous study has 
prospectively evaluated whether carbohydrate intake is associated with risk of developing 
PMS. 
Therefore, we evaluated the relationship between carbohydrate intake and the 
development of premenstrual syndrome in the Nurses’ Health Study 2 (NHS2) PMS Sub-
Study, a case-control study nested within the prospective NHS2. 
Methods 
Study Population 
The NHS2 is an ongoing prospective cohort study that has followed 116,686 US 
female nurses, aged 25-42 years in 1989, since the first mailed questionnaire.  
Information on health-related behaviors and medical history has been updated biennially 
and diet quadrennially for over 25 years.9   Response rates have been at least 89% for all 
questionnaire cycles.  The Institutional Review Board at Brigham and Women’s Hospital 
in Boston, MA approved the original NHS2 study protocol.   
Classification of PMS cases and controls 
The NHS2 PMS Sub-Study described previously,9,10 includes a subset of 
premenopausal women free of PMS prior to baseline in 1991.  Over 14 years of follow-
up (1993-2007 questionnaires), 4,108 participants reported new clinician-made diagnoses 
of PMS and the diagnosis year was used as the reference year.  Women who had never 
reported a diagnosis of PMS were randomly assigned a reference year between 1991 and 
2005, of which 3,248 were frequency matched to cases based on age and reference years.  
Women with a history of cancer other than non-melanoma skin cancer, endometriosis, 
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extremely irregular menstrual cycles, infertility, and hysterectomy prior to their reference 
year were excluded to limit the possibility that PMS-like symptoms were due to another 
condition.  Additionally, because of our interest in diet, those with implausible caloric 
intakes (i.e., those below 500 calories and above 3,500 calories) were also excluded.  
Potential cases and controls were then mailed a modified version of the Calendar of 
Premenstrual Experiences (COPE) questionnaire10,11  assessing occurrence, timing, and 
impact on several domains of daily functioning of 26 premenstrual symptoms in the 
specified 2-year period before their reference year to confirm case and control status.9   
PMS cases included 1,257 women that met clinical diagnostic guidelines for 
PMS.  Specifically, case criteria included: 1) ≥1 physical and ≥1 affective menstrual 
symptoms; 2) overall symptom severity of “moderate” or “severe” OR “moderate” or 
“severe” effect of symptoms on at least one life activity or relationship domains; 3) 
symptoms begin ≤14 days prior to start of menses; 4) symptoms end ≤4 days after start of 
menses; and 5) symptoms not present in the week after menses ended.9  Controls 
included 2,463 women that had no or minimal symptoms that did not impact daily 
function domains.  Control criteria included: 1) no PMS diagnosis; 2) either no menstrual 
symptoms OR an overall symptom severity of “minimal” or “mild”; and 3) either “no 
effect” or “mild” effect of symptoms on the life activities and relationship domains.  To 
minimize the likelihood for misclassification of the outcome, women who did not meet 
either case or control criteria were excluded from further analysis.  
Assessment of carbohydrate intake and other factors 
Intakes of carbohydrate containing foods were assessed via a semi-quantitative 
131-item food frequency questionnaire (FFQ) beginning in 1991 and subsequently every 
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four years after that.  We assessed the intake of total carbohydrates, glycemic index and 
load, dietary insulin index, sugar (i.e., total, natural, added, sucrose, fructose, lactose, 
maltose, and glucose), fiber (i.e., total, vegetable, legume, cereal, and fruit), whole and 
refined grains, bran, germ, and starch.  To calculate each woman’s total intake of 
carbohydrates, glycemic index, glycemic load, dietary insulin index, sugars, fibers, 
grains, bran, germ, and starch, the portion size of a single serving of each food or 
supplement was multiplied by the reported intake frequency.  The total amount of each 
food consumed was then multiplied by the nutrient content of the food item, and the 
nutrient contributions from all food items were summed.  All nutrients were then adjusted 
for the total energy intake using the residual method.12 
The validity of similar FFQs has been evaluated previously.12,28 The energy-
adjusted correlation between intakes reported by the FFQ and the mean of intake 
measured with two 1-week diet records was 0.59 for total carbohydrate intake.12 The 
energy-adjusted correlations between intakes reported by the FFQ and the mean intake 
measured with three 4-day weighed food records were 0.55 for total carbohydrate, 0.53 
for sugar, 0.40 for starch, 0.67 for fiber, 0.40 for glycemic index, and 0.38 for glycemic 
load.28   
For each participant, we evaluated carbohydrate intake at both baseline (1991) 
and 2-4 years before the specific reference year was assessed.  Dietary information was 
available for 3,660 Sub-Study participants at baseline and 3,638 women 2-4 years prior to 
reference year.  
Information on other factors potentially associated with PMS and diet were 
collected, such as age, smoking status, weight, pregnancy history, tubal ligation, and oral 
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contraceptive use on the biennial questionnaires.  Height and menstrual cycle 
characteristics were assessed on the 1989 questionnaire.  History of depression and 
antidepressant use were assessed on the menstrual cycle questionnaire.  Childhood 
trauma was assessed in 2001 on a separate questionnaire.13  Lastly, other nutrients such as 
vitamin D and calcium were assessed by FFQ.   
Statistical analysis 
Age-adjusted means and standard deviations for continuous variables and 
frequencies for categorical variables were calculated using generalized linear modeling to 
obtain distributions of demographic, behavioral, and lifestyle characteristics between 
cases and controls.    
We used unconditional logistic regression models to estimate relative risks (RR) 
of PMS for women across quintiles of carbohydrate intake and calculated 95% 
confidence intervals (CI) comparing the risk of PMS in each of the four highest quintiles 
compared to the lowest quintile adjusting for age.  Multivariable logistic regression was 
conducted controlling for age, reference year, age at menarche, body mass index (BMI; 
weight (kg)/height (m2)), physical activity, ever use of oral contraceptives, parity 
(pregnancies lasting ≥6 months), smoking status and quantity (pack-years), ever use of 
antidepressants, significant childhood trauma, alcohol intake, vitamin D from dietary 
sources and total intake of vitamins B6, B12, B1, B2, folate, iron, zinc, potassium, and 
calcium.  Additionally we mutually adjusted carbohydrate subtypes for one another.  
Finally, trend was assessed using the Mantel extension test for trend, where the median 
value of each carbohydrate category was entered into the regression model as a 
continuous variable.   
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We further assessed whether the relationship between carbohydrates and PMS 
varied by age at reference year (<40 versus ≥40) and smoking (past/never versus current) 
via stratified analyses.  The multiplicative interaction terms were evaluated using 
likelihood ratio tests, where the interaction terms were calculated as the products of a 
binary stratification factor and indicators of macronutrient quintile. 
Analyses were conducted using SAS 9.3 (SAS Institute Inc., Cary, NC, USA).  
Two-sided p-values <0.05 were considered statistically significant.   
Results 
Baseline characteristics of cases and controls are shown in Table 1.  Compared to 
controls, cases were younger and had a higher mean BMI both at baseline and at age 18.  
Cases were more likely to have used oral contraceptives, smoked, have been diagnosed 
with depression, used antidepressants, and had significant childhood trauma.  
Additionally, cases had lower intakes of vitamin D from food sources, calcium, and 
vitamins B6 and B12 at baseline.   
Total carbohydrate intake 2-4 years prior to the reference year was not associated 
with development of PMS (Table 2).  For example, the RR for the highest quintile of 
intake (median = 273.0 g/day) compared to the lowest quintile of intake (median = 185.0 
g/day) was 0.99 (95% CI = 0.74-1.33).  Similarly, glycemic index and glycemic load 
were not associated with the development of PMS.  While dietary insulin index was 
associated with lower risk of developing PMS in age-adjusted models, results adjusted 
for covariates were attenuated and no longer significant.  
Total sugar, added sugars, natural sugars, sucrose, fructose, and glucose were not 
associated with the development of PMS (Table 3).  High lactose intake was associated 
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with lower risk of PMS in age-adjusted analyses but after controlling for additional 
confounders such as BMI, smoking, and additional covariates, results were no longer 
significant.  Maltose intake was linearly related to PMS risk (p for trend = 0.004).  
Women with the highest intake (median = 3.0 g/day) had a 45% higher risk of developing 
PMS compared to women with the lowest intake (median = 1.2 g/day) (95% CI = 1.11-
1.89).  The higher risk associated with maltose remained significant when adjusting for 
other types of sugar (RR quintile 5 versus quintile 1 = 1.44; 95% CI = 1.10-1.87, p for 
trend = 0.007).   
Total fiber, vegetable fiber, cereal fiber, and fruit fiber were not associated with 
PMS development (Table 4).  Fiber from legume sources appeared to have a u-shaped 
association with PMS development, with lower risk of developing PMS in the third and 
fourth quintiles of intake compared to the first quintile.   
Intake of whole grains and refined grains were not associated with PMS 
development (Table 5).  Additionally, intake of bran, germ, and starch were not linearly 
associated with PMS development.   
Analyses evaluating carbohydrate intake at baseline in 1991 did not materially 
differ from the results shown.  As BMI may potentially lie within the causal path between 
carbohydrates and PMS, the analyses were repeated without adjusting for BMI and 
estimates were unchanged.  Analyses stratified by age and smoking status did not suggest 
effect modification of relative risks; statistical tests of interactions were all non-
significant (all p for interaction >0.05). 
Additional sensitivity analyses were performed to address the possibility of 
residual confounding, particularly in the model assessing maltose.  These models 
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evaluated the effect of controlling for continuous alcohol intake rather than categorical, 
as well as, adjusting for beer.  Neither of these steps affected the estimate from the 
primary analysis, suggesting that possible residual confounding by alcohol was of no 
consequence.  Lastly, we performed analysis to assess the possibility that women 
modified dietary consumption of maltose, total sugar, or total carbohydrates in response 
to pre-diagnosis symptoms and, therefore, observed associations reflected reverse 
causality.  To address this concern, we looked at the change from baseline in 
carbohydrate and sugar intake (intake at reference year – intake at baseline) in PMS cases 
and controls.  Change in carbohydrate or sugar intake was not significantly different 
among cases and controls, providing no suggestion of reverse causation in our 
observations.   
Discussion 
To our knowledge, this is one of the first studies to evaluate how carbohydrates 
and fibers are associated with the development of PMS.  Overall, we found little evidence 
that carbohydrate intake relates to PMS, though high intake of the sugar maltose was 
positively associated with risk.   
Whereas we have considered diet as related to risk of PMS development, prior 
research of the relation between carbohydrate intake and PMS has been limited to 
consideration of presence and/or severity of symptoms.  Among these previous studies, 
findings have been inconsistent.  Nagata and colleagues (2004) evaluated the relationship 
of carbohydrates and premenstrual symptoms among 189 Japanese women aged 19-34 
years.6  After controlling for age, smoking status, and other factors, the authors found that 
total intake of carbohydrates was not significantly associated with the total Menstrual 
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Distress Questionnaire score (r = -0.12; p >0.05) in the premenstrual phase.  Johnson and 
colleagues assessed macronutrient intake in healthy, normally menstruating women 
(n=26) without complaints of menstrual distress, not necessarily PMS, and found that 
percentage of calories from carbohydrates was positively associated with negative affect 
(r = 0.51; p <0.01) and behavior change (r = 0.42; p <0.05).26      
Cross and colleagues evaluated energy intakes during different phases of the 
menstrual cycle, including intake of carbohydrates, among women with PMS.29  They 
found statistically significant increases in intake of total carbohydrates (44.6% versus 
45.6% of kilocalories, p = 0.05) and simple sugars (18.9% versus 20.9%; p <0.001) from 
the postmenstrual to the premenstrual phase among women with PMS but not among 
women without PMS.  There was a non-significant decrease in intake of complex 
carbohydrates (25.6% versus 24.6% of kilocalories; p = 0.07).  However, these 
differences are very small and may not be clinically relevant.  Additionally, they did not 
evaluate whether these differences were significant in women with PMS compared to 
women without PMS.   
While we found no association with either glycemic index or load and risk of 
PMS, Murakami and colleagues found an inverse association of glycemic index and 
premenstrual symptoms in Japanese dietetic students (n=640) aged 18-22 years (p for 
trend=0.016) but no association with glycemic load.30  Similarly, they also found no 
association of fiber with premenstrual symptoms.   
A potential reason why the previous studies found associations whereas we found 
no associations is study design; the previous studies were all retrospective, while our 
study was prospective.  Women may be altering their diet in response to symptoms of 
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PMS as a method of managing them rather than carbohydrates or fiber leading to PMS 
development.  It is important to note that the relationship between fat and symptom 
experience, like the previous studies, may have different associations than fat with 
development of PMS, which our study assessed.  Secondly, the retrospective studies may 
be picking up carbohydrate cravings related to symptom experience rather than a 
physiological association when evaluated prospectively as the previous studies indicates 
that the eating behaviors differ by symptoms.  Thus, they may be a consequence of the 
symptoms rather than the cause.   
When looking at change in intake, the change in carbohydrate or sugar intake was 
not significantly different among cases and controls.  This indicates that carbohydrate 
intake or sugar intake do not appear to change over time differently in PMS cases than 
controls.  Women with PMS do not appear to increase their carbohydrate intake after 
diagnosis in response to symptoms to a greater extent than women without PMS.       
To our knowledge, previous studies have not evaluated sugar intake with regard 
to development of PMS.  Though two studies have assessed the association between 
intake of foods with high sugar contents in women with PMS or premenstrual symptom 
severity and found increases in both consumption premenstrually and increased symptom 
severity.27,29   
There have been few studies of specific sugars with PMS risk and none that 
considered maltose.  Maltose is a sugar found commonly in alcohols such as beer and 
foods such as yams and cereals.  Within the entire NHS2 cohort, in 1991 the highest 
sources of variation for maltose were tomato sauce and candy bars containing chocolate.  
Previous studies have shown that women with PMS consume higher intakes of alcohol 
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compared to women without PMS,7 including beer.31  However, the positive association 
between maltose and PMS found in this study is unlikely to be driven by alcohol as we 
controlled for alcohol intake.  Additionally, cases and controls had similar age-adjusted 
intakes of alcohol at baseline (3.1 g/day versus 3.1 g/day).  Furthermore, Bertone-
Johnson et al. (2009) found no association with alcohol intake and PMS development 
(RR = 1.19; 95% CI = 0.84-1.67) within the same PMS Sub-Study cohort.  The 
mechanism for the association between maltose and premenstrual syndrome is unknown 
and it is unclear whether the association was due to chance; thus, additional prospective 
studies are needed to confirm.  
Our study was nested within a large, ongoing prospective cohort of 116,686 
women and prospective charting of symptoms is infeasible in the context of large studies, 
as it is time intensive and cost prohibitive to collect diaries repeatedly from thousands of 
women.  However, we used strict criteria to classify PMS cases and, as controls, women 
with minimal symptoms that had no impact on function.9 Though some non-differential 
misclassification of the outcome is possible, its potential impact on findings is minimized 
by comparing the two ends of symptom spectrum and excluding those in the middle that 
met neither criteria.  Symptom recall is likely to be accurate for those who regularly 
experience severe symptoms that impair daily functioning and for those who regularly 
experience few, if any symptoms, and PMS status is unlikely to be misclassified between 
these two groups.9 Secondly, PMS was determined prospectively by report of clinician 
made diagnoses, which was then confirmed by retrospective questionnaire; this approach 
has been shown to be comparable reported prospective charting in a validation study.10   
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In conclusion, we did not observe evidence of an association of carbohydrate 
intake with PMS risk.  Additionally, high sugar intake and low fiber intake were also not 
associated with PMS risk.  Maltose may be associated with PMS development; however, 
since this is the first study to look at this relationship to our knowledge, further 
prospective studies are needed to confirm this association.   
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Table 2.1. Age-standardized characteristics of premenstrual syndrome cases and 
controls at baseline (n=3,660): NHS2 PMS Sub-Study, 1991-2005. 
  Cases (n=1234) 
Controls 
(n=2426)   
Characteristics1 Mean (SD) Mean (SD) p-value3 
Age, years 33.9 (4.2) 34.5 (3.9) <0.0001 
Body mass index (kg/m2)    
At baseline (1991) 24.6 (5.2) 23.7 (4.7) <0.0001 
At age 18 21.4 (3.3) 21.1 (3.1) 0.02 
Age at menarche, years 12.4 (1.4) 12.5 (1.4) 0.05 
Age at first birth, years2 25.9 (3.9) 26.1 (3.7) 0.10 
Number of full-term pregnancies (≥6 months) 1.6 (1.2) 1.6 (1.2) 0.36 
Physical activity, METS/week 22.9 (60.2) 23.6 (55.6) 0.74 
Pack-years of cigarette smoking 8.3 (64.7) 4.8 (50.2) 0.09 
Alcohol intake, g/day 3.1 (6.5) 3.1 (5.7) 0.99 
Total calorie intake, kcal/day 1826 (537) 1813 (520) 0.62 
Vitamin D intake food sources, IU/day4 255 (119) 266 (123) 0.01 
Total vitamin B6 intake, mg/day4 8.6 (26.3) 5.8 (15.6) <0.0001 
Total vitamin B12 intake, mg/day4 10.1 (14.2) 9.4 (8.5) 0.04 
Total thiamin intake, mg/day4 3.6 (8.2) 3.2 (6.0) 0.09 
Total riboflavin intake, mg/day4 4.1 (8.2) 3.6 (5.7) 0.07 
Total iron intake, mg/day4 24.9 (23.3) 25.8 (24.8) 0.35 
Total zinc intake, mg/day4 15.9 (10.7) 15.7 (10.3) 0.59 
Total potassium intake, mg/day4 2925 (499) 2897 (501) 0.17 
Total calcium intake, mg/day4 1030 (403) 1063 (421) 0.03 
    
  % % p-value3 
History of tubal ligation 15 16 0.66 
Oral contraceptive use    
Ever 85 77 <0.0001 
Current 12 11 0.33 
Duration > 4 years 43 37 0.001 
Smoking status    
Current 13 7 <0.0001 
Past 27 17 <0.0001 
Previously diagnosed with depression 15 7 <0.0001 
Previously used antidepressant 12 5 <0.0001 
History of childhood trauma 18 9 <0.0001 
1All characteristics, except age, standardized to the age distribution of participants in 1991 
2Limited to parous women 
3Calculated using generalized linear model 
4Energy adjusted values 
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Table 2.2. Age-adjusted and multivariate relative risks (RR)1 and 95% confidence 
intervals (CI) for dietary carbohydrate intakes 2-4 years prior to reference year and 
risk of premenstrual syndrome (n=3,638); NHS2 PMS Sub-Study, 1991-2005. 
  Q1 Q2 Q3 Q4 Q5 p-trend 
Total carbohydrate       
Median, g/day 185.0 210.0 227.2 246.0 273.0  
Case: Control Ratio 239:412 243:506 244:503 259:502 237:493  
RR       
Age-adjusted Ref 0.82 0.82 0.88 0.82 0.19 
Multivariate Ref 0.90 0.95 1.07 0.99 0.64 
95% CI2  0.70-1.15 0.73-1.23 0.82-1.40 0.74-1.33  
Glycemic index (GI)       
Median 49.4 52.2 53.9 55.4 57.8  
Case: Control Ratio 239:448 231:488 254:454 248:523 250:473  
RR       
Age-adjusted Ref 0.88 0.97 0.87 0.95 0.64 
Multivariate Ref 1.06 1.14 1.15 1.19 0.22 
95% CI2  0.83-1.36 0.88-1.47 0.87-1.50 0.89-1.59  
Glycemic load (GL)       
Median 96.0 110.9 121.8 133.0 150.1  
Case: Control Ratio 234:413 233:490 267:512 250:498 238:503  
RR       
Age-adjusted Ref 0.83 0.90 0.87 0.81 0.14 
Multivariate Ref 0.99 1.07 1.12 1.08 0.45 
95% CI2  0.77-1.27 0.83-1.38 0.85-1.47 0.81-1.43  
Dietary insulin index (DII)      
Median 37.9 41.2 43.4 45.7 49.1  
Case: Control Ratio 218:385 259:439 226:483 256:556 263:553  
RR       
Age-adjusted Ref 1.03 0.80 0.79 0.81 0.01 
Multivariate Ref 1.13 0.92 0.93 1.06 0.91 
95% CI2  0.87-1.46 0.70-1.19 0.71-1.21 0.80-1.39  
1Adjusted for age (continuous), reference year (91-92, 93, 94-96, 97-98, 99-00, 01-02, 03-04), age at 
menarche (continuous), current body mass index (≤19.9, 20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.9, ≥30 
kg/m2), physical activity (<3, 3-8, 9-17, 18-26, 27-41, ≥42 METs), oral contraceptives (none, 1-23, 24-71, 
72-119, ≥120 months), parity (nulliparous, 1-2, 3-4, ≥5 pregnancies >6 months), smoking (never, past 1-14, 
past 15-34, past 35+, current 1-14, current 15-34, current 35+ cig/day), previous use of antidepressants 
(never, ever), significant childhood trauma (5, 6-10, 11-15, 16-20, 21-25), alcohol intake (quintiles), 
vitamin D from dietary sources (quintiles) and quintiles of total intake for vitamins B6, B12, B1, B2, folate, 
iron, zinc, potassium, and calcium at 2-4 years prior to reference year. 
295% CI is for multivariable model. 
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Table 2.3. Age-adjusted and multivariate relative risks (RR)1 and 95% confidence 
intervals (CI) for dietary sugar intakes 2-4 years prior to reference year and risk of 
premenstrual syndrome (n=3,638); NHS2 PMS Sub-Study, 1991-2005. 
  Q1 Q2 Q3 Q4 Q5 p-trend 
Total sugar       
Median, g/day 69.1 87.3 102.6 119.1 147.9  
Case: Control Ratio 252:452 262:485 226:506 271:521 211:452  
RR       
Age-adjusted Ref 0.96 0.79 0.92 0.81 0.08 
Multivariate Ref 1.04 0.89 1.04 0.83 0.22 
95% CI2  0.82-1.33 0.69-1.15 0.81-1.34 0.63-1.10  
Added sugar       
Median, g/day 25.1 36.5 46.3 59.6 86.7  
Case: Control Ratio 242:438 262:511 260:572 233:484 225:411  
RR       
Age-adjusted Ref 0.92 0.81 0.85 0.96 0.85 
Multivariate Ref 1.02 0.90 0.97 1.01 0.98 
95% CI2  0.81-1.30 0.71-1.14 0.75-1.25 0.76-1.33  
Natural sugar       
Median, g/day 29.0 41.1 51.7 62.9 80.4  
Case: Control Ratio 225:399 256:483 264:492 248:546 229:496  
RR       
Age-adjusted Ref 0.94 0.96 0.81 0.82 0.03 
Multivariate Ref 1.01 0.99 0.81 0.77 0.08 
95% CI2  0.77-1.31 0.74-1.31 0.59-1.11 0.54-1.10  
Sucrose       
Median, g/day 24.1 33.0 39.8 48.2 62.5  
Case: Control Ratio 242:458 266:510 254:535 248:475 212:438  
RR       
Age-adjusted Ref 0.97 0.89 0.97 0.90 0.41 
Multivariate Ref 1.04 0.92 1.05 0.91 0.54 
95% CI2  0.82-1.32 0.73-1.18 0.82-1.35 0.70-1.19  
Fructose       
Median, g/day 11.8 16.6 20.7 25.5 34.8  
Case: Control Ratio 249:483 257:486 246:519 239:483 231:445  
RR       
Age-adjusted Ref 1.02 0.91 0.95 1.00 0.85 
Multivariate Ref 1.13 0.92 1.01 0.95 0.50 
95% CI2  0.89-1.44 0.72-1.17 0.79-1.30 0.73-1.24  
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Table 2.3, Continued. 
  Q1 Q2 Q3 Q4 Q5 p-trend 
Lactose       
Median, g/day 4.0 9.5 14.8 21.8 35.0  
Case: Control Ratio 219:413 231:430 267:505 262:472 243:596  
RR       
Age-adjusted Ref 0.99 0.98 1.02 0.74 0.005 
Multivariate Ref 1.04 1.13 1.08 0.75 0.11 
95% CI2  0.79-1.37 0.83-1.54 0.76-1.54 0.49-
1.14 
 
Maltose       
Median, g/day 1.2 1.6 1.9 2.3 3.0  
Case: Control Ratio 196:444 253:518 243:497 276:525 254:432  
RR       
Age-adjusted Ref 1.09 1.09 1.18 1.31 0.01 
Multivariate Ref 1.17 1.20 1.33 1.45 0.004 
95% CI2  0.91-1.50 0.93-1.54 1.03-1.71 1.11-
1.89 
 
Glucose       
Median, g/day 12.0 16.2 19.5 23.8 32.2  
Case: Control Ratio 251:501 255:489 258:506 245:474 213:446  
RR       
Age-adjusted Ref 1.03 1.01 1.02 0.94 0.55 
Multivariate Ref 1.14 1.06 1.08 0.91 0.31 
95% CI2  0.90-1.45 0.83-1.35 0.84-1.38 0.69-
1.18 
 
1Adjusted for age, reference year, age at menarche, body mass index, physical activity, oral contraceptive 
use, parity, smoking status, ever use of antidepressants, significant childhood trauma, alcohol intake, 
vitamin D from dietary sources and total intake of vitamins B6, B12, B1, B2, folate, iron, zinc, potassium, 
and calcium at 2-4 years prior to reference year. 
295% CI is for multivariable model. 
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Table 2.4. Age-adjusted and multivariate relative risks (RR)1 and 95% confidence 
intervals (CI) for dietary fiber intakes 2-4 years prior to reference year and risk of 
premenstrual syndrome (n=3,638); NHS2 PMS Sub-Study, 1991-2005. 
  Q1 Q2 Q3 Q4 Q5 p-trend 
Total fiber         
Median, g/day 12.6 15.5 17.9 20.8 25.5  
Case: Control Ratio 233:454 238:478 247:518 253:499 251:467  
RR       
Age-adjusted Ref 1.00 0.95 1.02 1.10 0.36 
Multivariate Ref 1.04 0.98 1.08 1.11 0.48 
95% CI2  0.81-1.35 0.75-1.29 0.81-1.45 0.80-1.53  
Vegetable fiber       
Median, g/day 3.2 4.6 6.0 7.5 10.5  
Case: Control Ratio 244:480 239:515 257:518 241:475 241:428  
RR       
Age-adjusted Ref 0.93 1.02 1.05 1.16 0.08 
Multivariate Ref 0.92 1.04 1.00 1.03 0.70 
95% CI2  0.73-1.18 0.81-1.33 0.77-1.31 0.77-1.37  
Legume fiber       
Median, g/day 0.1 0.4 0.8 1.1 2.2  
Case: Control Ratio 245:437 233:487 225:502 247:530 272:460  
RR       
Age-adjusted Ref 0.86 0.81 0.85 1.10 0.11 
Multivariate Ref 0.82 0.80 0.78 1.02 0.36 
95% CI2  0.65-1.05 0.61-1.00 0.61-0.99 0.80-1.31  
Cereal fiber       
Median, g/day 3.1 4.3 5.4 6.7 9.4  
Case: Control Ratio 213:368 221:441 249:483 263:581 276:543  
RR       
Age-adjusted Ref 0.86 0.89 0.78 0.87 0.28 
Multivariate Ref 0.93 1.09 0.99 1.15 0.21 
95% CI2  0.72-1.21 0.84-1.42 0.76-1.30 0.87-1.52  
Fruit fiber       
Median, g/day 1.1 2.0 2.9 4.1 6.3  
Case: Control Ratio 245:486 230:425 245:561 265:477 237:467  
RR       
Age-adjusted Ref 1.08 0.87 1.12 1.03 0.63 
Multivariate Ref 1.18 0.94 1.14 0.94 0.54 
95% CI2  0.92-1.51 0.73-1.20 0.88-1.48 0.71-1.25  
1Adjusted for age, reference year, age at menarche, body mass index, physical activity, oral contraceptive 
use, parity, smoking status, ever use of antidepressants, significant childhood trauma, alcohol intake, 
vitamin D from dietary sources and total intake of vitamins B6, B12, B1, B2, folate, iron, zinc, potassium, 
and calcium at 2-4 years prior to reference year. 
295% CI is for multivariable model. 
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Table 2.5.  Age-adjusted and multivariate relative risks (RR)1 and 95% confidence 
intervals (CI) for dietary grain intakes 2-4 years prior to reference year and risk of 
premenstrual syndrome (n=3,638); NHS2 PMS Sub-Study, 1991-2005. 
  Q1 Q2 Q3 Q4 Q5 p-trend 
Whole grains       
Median, g/day 5.8 11.9 18.4 26.7 43.5  
Case: Control Ratio 210:419 227:437 264:499 259:530 262:531  
RR       
Age-adjusted Ref 1.04 1.07 0.98 0.99 0.67 
Multivariate Ref 1.04 1.08 1.05 1.10 0.55 
95% CI2  0.80-1.34 0.83-1.39 0.81-1.37 0.84-1.44  
Refined grains       
Median, g/day 39.2 52.0 61.8 73.6 93.2  
Case: Control Ratio 212:376 241:466 245:479 263:535 261:560  
RR       
Age-adjusted Ref 0.90 0.90 0.87 0.81 0.08 
Multivariate Ref 1.00 1.05 1.10 1.12 0.30 
95% CI2  0.77-1.28 0.82-1.36 0.85-1.43 0.86-1.47  
Bran       
Median, g/day 0.9 2.3 4.2 6.6 12.6  
Case: Control Ratio 204:387 246:480 251:501 267:554 254:494  
RR       
Age-adjusted Ref 0.98 0.96 0.92 0.98 0.85 
Multivariate Ref 0.92 0.92 1.01 1.09 0.23 
95% CI2  0.71-1.18 0.71-1.20 0.78-1.32 0.82-1.44  
Germ       
Median, g/day 0.3 0.5 0.8 1.2 2.2  
Case: Control Ratio 227:408 248:516 235:469 250:495 262:528  
RR       
Age-adjusted Ref 0.86 0.90 0.90 0.89 0.65 
Multivariate Ref 0.77 0.91 0.91 0.87 0.88 
95% CI2  0.60-0.98 0.71-1.18 0.70-1.17 0.67-1.13  
Starch       
Median, g/day 57.7 70.2 80.2 91.3 109.1  
Case: Control Ratio 219:393 237:453 253:485 239:541 274:544  
RR       
Age-adjusted Ref 0.93 0.94 0.79 0.90 0.20 
Multivariate Ref 0.94 1.06 0.93 1.17 0.25 
95% CI2  0.73-1.21 0.82-1.37 0.71-1.21 0.89-1.53  
1Adjusted for age, reference year, age at menarche, body mass index, physical activity, oral contraceptive 
use, parity, smoking status, ever use of antidepressants, significant childhood trauma, alcohol intake, 
vitamin D from dietary sources and total intake of vitamins B6, B12, B1, B2, folate, iron, zinc, potassium, 
and calcium at 2-4 years prior to reference year. 
295% CI is for multivariable model. 
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CHAPTER 3 
PROTEIN INTAKE AND THE RISK OF PREMENSTRUAL SYNDROME 
Abstract 
Premenstrual syndrome (PMS) is a cyclical late luteal phase disorder of the 
menstrual cycle whereby symptoms affect daily functioning.  Up to 20% of reproductive 
aged women are estimated to meet clinical diagnostic guidelines for PMS.  Protein intake 
may be a modifiable risk factor for PMS, as many amino acids found in dietary protein 
are precursors of neurotransmitters, of which alterations in normal levels may lead to 
PMS.  We examined the relationship between protein intake and the risk of incident PMS 
among participants in the PMS Sub-Study of the prospective Nurses’ Health Study II 
cohort.  Incident cases of PMS (n=1,257) were identified by self-reported diagnosis 
during 14 years of follow-up and validated using questionnaire.  Controls (n=2,463) were 
women who did not report a diagnosis of PMS during follow-up and confirmed 
experiencing minimal premenstrual symptoms.  Protein intake was assessed 4 times 
during follow-up by food frequency questionnaire.  Unconditional multivariable logistic 
regression was used to estimate relative risks (RR) and 95% confidence intervals (CI).  
After adjustments for smoking, body mass index, B vitamins, and other factors, neither 
total protein intake at baseline nor 2-4 years prior to reference year were associated with 
PMS development.  Additionally, intakes of specific sources of protein and amino acids 
were not associated with PMS.  Overall, protein consumption was not associated with 
risk of developing premenstrual syndrome.   
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Introduction 
Up to 20% of reproductive aged women meet clinical diagnostic criteria for 
premenstrual syndrome (PMS),1,2 a cyclical disorder characterized by physical and 
emotional symptoms occurring during the late luteal phase of the menstrual cycle and 
abating within a few days following the onset of menses.  While the etiology of PMS is 
still largely unknown, an interaction between hormonal, neural, genetic, psychosocial, 
and dietary factors likely contributes.24   
Because of the limited efficacy of pharmaceutical treatments for PMS, there is a 
need for identifying preventive or modifiable risk factors such as diet.  High protein 
intake and intake of specific amino acids may plausibly lower PMS risk, as tryptophan, 
glutamate, and other amino acids are precursors to neurotransmitters implicated in PMS 
etiology.  A small number of retrospective studies of relationships between premenstrual 
symptoms consumption of protein have reported inconsistent findings.6,32,33  Among 
studies that have reported an association, issues related to establishing temporal ordering 
of dietary factors and PMS have resulted in uncertainty whether increased protein intake 
or amino acid intake precedes the development of PMS or whether intake is affected by 
symptom occurrence.  To our knowledge, no previous study has prospectively evaluated 
whether protein intake is associated with risk of developing PMS. 
Therefore, we evaluated the relationship between protein intake and the 
development of premenstrual syndrome in the Nurses’ Health Study 2 (NHS2) PMS Sub-
Study, a case-control study nested within the prospective NHS2. 
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Methods 
Study Population 
The NHS2 is an ongoing prospective cohort study that has followed 116,686 US 
female nurses, aged 25-42 years in 1989, since the first mailed questionnaire.  
Information on health-related behaviors and medical history has been updated biennially 
and diet quadrennially for over 25 years.9   Response rates have been at least 89% for all 
questionnaire cycles.  The Institutional Review Board at Brigham and Women’s Hospital 
in Boston, MA approved the original NHS2 study protocol.   
Classification of PMS cases and controls 
The NHS2 PMS Sub-Study, described previously,9,10 includes a subset of 
premenopausal women free of PMS prior to baseline in 1991.  Over 14 years of follow-
up (1993-2007 questionnaires), 4,108 participants reported new clinician-made diagnoses 
of PMS.  For these women we assigned diagnosis year as their reference year.  Women 
who had never reported a diagnosis of PMS were randomly assigned a reference year 
between 1991 and 2005, of which 3,248 were frequency matched to cases based on age 
and reference years.  Among both groups, women with a history of cancer other than 
non-melanoma skin cancer, endometriosis, extremely irregular menstrual cycles, 
infertility, and hysterectomy prior to their reference year were excluded to limit the 
possibility that PMS-like symptoms were due to another condition.  Additionally, 
because of our interest in diet, those with implausible caloric intakes (i.e., those below 
500 calories and above 3,500 calories) were also excluded.  Potential cases and controls 
were then mailed a modified version of the Calendar of Premenstrual Experiences 
(COPE) questionnaire10,11  assessing occurrence, timing, and impact on several domains 
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of daily functioning of 26 premenstrual symptoms in the specified 2-year period before 
their individual reference year to confirm case and control status.9   
PMS cases included 1,257 women that met clinical diagnostic guidelines for 
PMS.  Specifically, case criteria included: 1) ≥1 physical and ≥1 affective menstrual 
symptoms; 2) overall symptom severity of “moderate” or “severe” OR “moderate” or 
“severe” effect of symptoms on at least one life activity or relationship domains; 3) 
symptoms begin ≤14 days prior to start of menses; 4) symptoms end ≤4 days after start of 
menses; and 5) symptoms not present in the week after menses ended.9  Controls 
included 2,463 women that had no or minimal symptoms that did not impact daily 
function domains.  Control criteria included: 1) no PMS diagnosis; 2) either no menstrual 
symptoms OR an overall symptom severity of “minimal” or “mild”; and 3) either “no 
effect” or “mild” effect of symptoms on the life activities and relationship domains.  To 
minimize the likelihood for misclassification of cases as controls the outcome, women 
who did not meet either case or control criteria were excluded from further analysis.  
Assessment of protein intake and other factors 
Intakes of protein containing foods were assessed via a semi-quantitative 131-
item food frequency questionnaire (FFQ) beginning in 1991 and subsequently every four 
years thereafter.  We assessed the intake of total protein, sources of protein (i.e., animal, 
vegetable, dairy), the ratio of animal: vegetable protein, and specific amino acids (i.e., 
tryptophan, tyrosine, glutamate).  To calculate each woman’s total intake of protein and 
amino acids, the portion size of a single serving of each food or supplement was 
multiplied by the reported intake frequency.  The total amount of each food consumed 
was then multiplied by the protein or amino acid nutrient content of the food item, and 
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contributions from all food items were summed.  Protein intake was then adjusted for the 
total energy intake using the residual method.12 
The validity of similar FFQs for measuring total protein intake has been 
demonstrated previously.12 In an analysis of 92 women, the energy-adjusted correlation 
between intakes reported by the FFQ and the mean of intake measured with two 1-week 
diet records was 0.42 for total protein intake.12  
For each participant, we evaluated protein intake at both baseline (1991) and 2-4 
years before her individual reference year.  Dietary information was available for 3,660 
Sub-study participants at baseline and 3,638 women 2-4 years prior to reference year.  
Information on other factors potentially associated with PMS and diet were 
collected on the biennial questionnaires, including age, smoking status, weight, 
pregnancy history, tubal ligation, and oral contraceptive use.  Height and menstrual cycle 
characteristics were assessed on the 1989 questionnaire.  History of depression and 
antidepressant use were assessed on the menstrual cycle questionnaire.  Childhood 
trauma was assessed in 2001 on a separate questionnaire.13  Lastly, macronutrients and 
micronutrients including vitamin D, B vitamins, calcium, and other minerals were 
assessed by FFQ.   
Statistical analysis 
Age-adjusted means and standard deviations for continuous variables and 
frequencies for categorical variables were calculated using generalized linear modeling to 
compare distributions of demographic, behavioral, and lifestyle characteristics between 
cases and controls.    
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We used unconditional logistic regression to estimate relative risks (RR) and 95% 
confidence intervals (CI) of PMS for women across quintiles of protein and amino acid 
intake.  Multivariable logistic regression was conducted to assess the relationship 
between protein intake and PMS risk, controlling for age, reference year, age at 
menarche, body mass index (BMI; weight (kg)/height (m2)), physical activity, ever use of 
oral contraceptives, parity (pregnancies lasting ≥6 months), smoking status and quantity 
(pack-years), ever use of antidepressants, significant childhood trauma, vitamin D from 
dietary sources and total intake of vitamins B6, B1, iron, and zinc.  
Additionally we mutually adjusted protein sources subtypes for one another, to 
control for potential confounding by variations in protein sources, where potential 
associations could be due to increases or decreases in the other protein sources.  For 
example, vegetable protein was adjusted for intake of dairy and animal protein.  Linear 
trend across quintiles was assessed using the Mantel extension test for trend, where the 
median value of each protein category was entered into the regression model as a 
continuous variable.   
We further assessed whether a relation between protein and amino acid intake and 
PMS varied by age at reference year (<40 versus ≥40 years) and smoking status 
(past/never versus current) via stratified analyses.  The multiplicative interaction terms 
were evaluated using likelihood ratio tests, where the interaction terms were calculated as 
the products of a binary stratification factor and indicators of macronutrient quintile.   
To assess the possibility that associations between higher protein intake and risk 
of PMS could be due to lower intake of fats or carbohydrates we conducted substitution 
analyses.  For example, we compared associations when protein was substituted for fat by 
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including terms in the model for the percent kcal from protein, the percent kcal from 
carbohydrates, the percent kcal from alcohol, and total kcal in the model, excluding 
percent kcal from fat.  Additional substitution models were also conducted looking at 
substitutions for carbohydrates and fats.   
Analyses were conducted using SAS 9.3 (SAS Institute Inc., Cary, NC, USA).  
Two-sided p-values <0.05 were considered statistically significant.   
Results 
Baseline characteristics of cases and controls are shown in Table 1.  Compared to 
controls, cases were younger and had a higher mean BMI both at baseline and at age 18.  
Cases were more likely to have used oral contraceptives, smoked, have been diagnosed 
with depression, used antidepressants, and had significant childhood trauma.  
Additionally, cases had lower intakes of vitamin D from food sources, calcium, and 
vitamins B6 and B12 at baseline.   
Total protein intake 2-4 years prior to the reference year was not associated with 
development of PMS (Table 2).  Overall, sources of protein were not associated with the 
development of PMS.  While higher intakes of dairy protein were associated with lower 
risk of PMS in the age-adjusted model, the results were no longer significant after 
adjustments for vitamin D, B vitamins, and other covariates.  Higher vegetable protein 
intake was non-significantly associated with increased risk of PMS in multivariable-
adjusted models (p for trend = 0.07; RR quintile 5 versus quintile 2 = 1.27; 95% CI = 
0.97-1.66).  Lastly, intakes of tryptophan, tyrosine, and glutamate were not associated 
with the development of PMS (Table 3).   
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Analyses evaluating protein and amino acid intake at baseline in 1991 were 
similar to results for reference year presented (results not shown).  For example, the RR 
for total protein comparing the highest quintiles to the lowest quintile was 0.97 (95% CI 
= 0.71-1.32).  As BMI may potentially lie within the causal path between protein intake 
and PMS, the analyses were repeated without BMI and estimates were unchanged.  
Analyses stratified by smoking status did not suggest effect measure modification and 
there were no significant interactions found.  However, the association between protein 
and risk of PMS did differ by age at diagnosis.  For total protein, women that were 40 or 
above at reference year had higher risk of PMS development with increasing protein 
intake, whereas women below 40 at reference year had lower risk of PMS development 
with increasing protein intake (p for interaction = 0.009).  Additionally, interactions were 
significant for animal protein and vegetable protein sources (p for interactions < 0.01).  
For animal protein, for those 40 or above at reference year, PMS risk was higher for 
increasing animal protein intake and for those 40 and above during reference year, PMS 
risk was inverse with increasing animal protein intake.  Whereas, the opposite was found 
for vegetable protein. 
Table 4 presents the results of substation models, where we assessed the effect of 
substituting different macronutrients for others.  This looks at the effect of the changes in 
other macronutrients instead of looking at absolute values only.  In age-adjusted models, 
substitution   protein or fats for carbohydrate calories appeared to increase risk of 
developing PMS.  Substitution of protein for carbohydrate calories was associated with a 
13% increase in PMS risk (95% CI = 1.01-1.26).  However, after adjustment for 
micronutrient intake and other covariates, substitution of protein for carbohydrate 
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calories was not associated with PMS in multivariable models (RRcontinuous = 1.01; 95% 
CI = 0.83-1.22).  Similarly, substitution of fat for carbohydrate calories was not 
associated after adjusting for micronutrients and other covariates (RRcontinuous = 1.02; 95% 
CI = 0.87-1.18).  Additional substitutions for fat or carbohydrates were not associated 
with PMS risk.  
Discussion 
To our knowledge, this is one of the first studies to evaluate prospectively how 
protein and amino acid intake are associated with the development of PMS.  Overall, we 
found little evidence that protein intake relates to PMS.     
Results from previous studies of protein intake and premenstrual symptoms have 
been inconsistent.  Nagata and colleagues (2004) evaluated the relationship of total 
protein intake and premenstrual symptoms among Japanese women aged 19-34 (n=189).6  
Total protein (mean protein intake = 76.9 g/day; SD = 35.3 g/day) was found to be not 
correlated with change in total menstrual distress scores in the premenstrual phase.  
Barnard (2000) conducted a crossover study among 33 women comparing a low-fat 
vegetarian diet to normal diet with B-vitamin supplements and found that the low-fat 
vegetarian diet decreased the duration of premenstrual symptoms.32  Intakes of protein 
and fat were significantly different between the normal diet (mean protein intake = 59.8 
g/day; SD = 17.7 g/day) and low-fat vegetarian diet (mean protein intake = 43.5 g/day; 
SD = 11.5 g/day).  However, it is unclear whether this is due to the vegetarian diet, lower 
protein intakes, B vitamin supplement, and/or the low fat diet.  Lastly, Steinberg (1999) 
conducted a clinical trial assessing supplementation of tryptophan (6 g) in women with 
PMDD for 17 days, where supplementation with tryptophan (n=37) was more effective 
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than placebo (n=34) in reducing mood symptom severity among women with PMDD.  
Our study found no association with tryptophan and risk of developing PMS; however, 
our mean intake of tryptophan was less than 1 gram (mean = 0.98 g/day; SD = 0.17 
g/day).   
Substitution of protein for fat or carbohydrates was not associated with risk of 
developing PMS after adjusting for potential confounders.  This is consistent with our 
previous findings (cite fat and carb paper) that fat and carbohydrates were not associated 
with PMS risk.  This further suggests that macronutrient intake is not associated with 
PMS risk after controlling for confounding by micronutrients and other covariates.    
Differences in our results compared to previous study findings could potentially 
be due to confounding by micronutrients.  Nagata did not adjust for micronutrients such 
as vitamin D or B vitamins.6  However, when we controlled for several micronutrients we 
still found no association.  The reduction in premenstrual symptom severity for the 
crossover study by Barnard may have been due to additional differences other than fat 
intake and source of protein, including differences in micronutrient intakes.32   
One potential reason why the previous studies found associations with tryptophan 
whereas we found no associations is study design.  The previous studies were treatment 
trials for premenstrual symptoms, while our study assessed risk of PMS.  Factors that are 
associated with treatment of existing PMS may not be similarly related to risk of 
developing PMS.  Additionally, the dose in the treatment trials was substantially higher 
than the average intake of tryptophan in our study.  If potential benefits of tryptophan are 
dependent upon higher intakes, we may not have observed associations because of the 
lower levels in our study.  Women may be altering their diet in response to symptoms of 
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PMS as a method of managing them rather than protein or amino acids leading to PMS 
development.   
Due to the large prospective cohort study design, prospective charting was not 
feasible; however, misclassification of the outcome is minimized by comparing the two 
ends of symptom spectrum and excluding those in the middle that met criteria neither for 
cases nor for controls.  Symptom recall is likely to be accurate for those who regularly 
experience severe symptoms that impair daily functioning and for those who regularly 
experience few, if any symptoms, and is unlikely to be misclassified between these two 
groups.9 Secondly, participants had prospectively reported incident PMS diagnoses by a 
clinician which were then confirmed by validated retrospective questionnaire.  Thus, 
those meeting Mortola criteria for PMS were comparable to those that met the Mortola 
criteria and additionally reported prospective charting.10   
In conclusion, we did not observe evidence that protein or amino acid intake was 
associated with PMS risk.  Furthermore, macronutrient intake overall was not associated 
with PMS after adjusting for micronutrients.    
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Table 3.1. Age-standardized characteristics of premenstrual syndrome cases and 
controls at baseline (n=3,660); NHS2 PMS Sub-Study, 1991-2005. 
  Cases (n=1234) 
Controls 
(n=2426)   
Characteristics1 Mean (SD) Mean (SD) p-value3 
Age, years 33.9 (4.2) 34.5 (3.9) <0.0001 
Body mass index (kg/m2)    
At baseline (1991) 24.6 (5.2) 23.7 (4.7) <0.0001 
At age 18 21.4 (3.3) 21.1 (3.1) 0.02 
Age at menarche, years 12.4 (1.4) 12.5 (1.4) 0.05 
Age at first birth, years2 25.9 (3.9) 26.1 (3.7) 0.10 
Number of full-term pregnancies (≥6 months) 1.6 (1.2) 1.6 (1.2) 0.36 
Physical activity, METS/week 22.9 (60.2) 23.6 (55.6) 0.74 
Pack-years of cigarette smoking 8.3 (64.7) 4.8 (50.2) 0.09 
Alcohol intake, g/day 3.1 (6.5) 3.1 (5.7) 0.99 
Total calorie intake, kcal/day 1826 (537) 1813 (520) 0.62 
Vitamin D intake food sources, IU/day4 255.4 (119.1) 266.8 (122.7) 0.01 
Total vitamin B6 intake, mg/day4 8.6 (26.3) 5.8 (15.6) <0.0001 
Total vitamin B12 intake, mg/day4 10.1 (14.2) 9.4 (8.5) 0.04 
Total thiamin intake, mg/day4 3.6 (8.2) 3.2 (6.0) 0.09 
Total riboflavin intake, mg/day4 4.1 (8.2) 3.6 (5.7) 0.07 
Total iron intake, mg/day4 24.9 (23.3) 25.8 (24.8) 0.35 
Total zinc intake, mg/day4 15.9 (10.7) 15.7 (10.3) 0.59 
Total potassium intake, mg/day4 2925 (499) 2897 (501) 0.17 
Total calcium intake, mg/day4 1030 (403) 1063 (421) 0.03 
    
  % % p-value3 
History of tubal ligation 15 16 0.66 
Oral contraceptive use    
Ever 85 77 <0.0001 
Current 12 11 0.33 
Duration > 4 years 43 37 0.001 
Smoking status    
Current 13 7 <0.0001 
Past 27 17 <0.0001 
Previously diagnosed with depression 15 7 <0.0001 
Previously used antidepressant 12 5 <0.0001 
History of childhood trauma 18 9 <0.0001 
1All characteristics, except age, standardized to the age distribution of participants in 1991 
2Limited to parous women 
3Calculated using generalized linear modeling 
4Energy-adjusted values 
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Table 3.2. Age-adjusted and multivariate relative risks (RR)1 and 95% confidence 
intervals (CI) for dietary protein intakes 2-4 years prior to reference year and risk 
of premenstrual syndrome (n=3,638); NHS2 PMS Sub-Study, 1991-2005. 
 Q1 Q2 Q3 Q4 Q5 Ptrend 
Total protein       
Median, g/day 66.6 77.3 84.8 92.1 103.6  
Case: Control Ratio 236:419 233:556 269:541 272:515 212:383  
RR       
Age-adjusted Ref 0.73 0.88 0.93 0.98 0.49 
Model 1 Ref 0.73 0.89 0.89 0.93 0.90 
95% CI2  0.56-0.93 0.68-1.15 0.68-1.17 0.68-1.25  
Animal Protein       
Median, g/day 41.9 53.9 61.7 69.6 81.6  
Case: Control Ratio 236:455 245:521 284:549 250:471 207:418  
RR       
Age-adjusted Ref 0.90 0.99 1.02 0.95 0.99 
Model 1 Ref 0.86 0.95 0.93 0.81 0.29 
95% CI2  0.67-1.10 0.74-1.23 0.70-1.22 0.60-1.09  
Vegetable Protein       
Median, g/day 17.2 20.3 22.7 25.3 30.0  
Case: Control Ratio 226:414 244:488 243:491 237:512 272:509  
RR       
Age-adjusted Ref 0.94 0.92 0.87 1.01 0.95 
Model 1 Ref 1.00 1.02 0.98 1.27 0.07 
95% CI2  0.78-1.28 0.80-1.32 0.76-1.28 0.97-1.66  
Dairy Protein       
Median, g/day 7.9 12.5 16.2 21.3 29.9  
Case: Control Ratio 201:379 249:429 251:495 257:516 264:596  
RR       
Age-adjusted Ref 1.07 0.93 0.90 0.80 0.01 
Model 1 Ref 1.19 1.09 0.98 0.91 0.26 
95% CI2  0.91-1.54 0.82-1.43 0.73-1.31 0.66-1.27  
Animal: Vegetable       
Median, g/day 1.6 2.3 2.8 3.4 4.3  
Case: Control Ratio 239:525 265:481 257:519 255:472 206:419  
RR       
Age-adjusted Ref 1.26 1.08 1.19 1.04 0.72 
Model 1 Ref 1.08 0.95 1.01 0.85 0.21 
95% CI2  0.85-1.37 0.75-1.21 0.78-1.31 0.64-1.13  
1Adjusted for age (continuous), reference year (91-92, 93, 94-96, 97-98, 99-00, 01-02, 03-04), age at 
menarche (continuous), body mass index (≤19.9, 20.0-22.9, 22.5-24.9, 25.0-27.4, 27.5-29.9, ≥30 kg/m2), 
physical activity (<3, 3-8, 9-17, 18-26, 27-41, ≥42 METs), oral contraceptive use (none, 1-23, 24-71, 72-
119, ≥120 months), parity (nulliparous, 1-2, 3-4, ≥5 pregnancies >6 months), smoking status (never, past 1-
14, past 15-34, past 35+, current 1-14, current 15-34, current 35+ cig/day), ever use of antidepressants 
(never, ever), childhood trauma score (5, 6-10, 11-15, 16-20, 21-25), vitamin D from dietary sources 
(quintiles) and quintiles of total intake for vitamins B6, B1, iron, and zinc at 2-4 years before reference year. 
295% CI is for multivariable model. 
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Table 3.3. Age-adjusted and multivariate relative risks (RR)1 and 95% confidence 
intervals (CI) for amino acid intakes (g/day) 2-4 years prior to diagnosis and risk of 
premenstrual syndrome (n=3638); NHS2 PMS Sub-Study, 1991-2005. 
 Q1 Q2 Q3 Q4 Q5 Ptrend 
Tryptophan       
Median, g/day 0.8 0.9 1.0 1.1 1.2  
Case: Control Ratio 229:417 232:523 284:580 270:486 207:410  
RR       
Age-adjusted Ref 0.78 0.89 1.00 0.89 0.84 
Model 1 Ref 0.82 0.98 1.05 0.89 0.98 
95% CI2  0.64-1.05 0.75-1.26 0.80-1.39 0.66-1.21  
Tyrosine        
Median, g/day 2.3 2.7 3.0 3.3 3.7  
Case: Control Ratio 226:407 244:552 272:529 259:491 221:437  
RR       
Age-adjusted Ref 0.80 0.91 0.95 0.87 0.92 
Model 1 Ref 0.81 1.00 0.91 0.89 0.71 
95% CI2  0.63-1.05 0.76-1.30 0.68-1.21 0.65-1.21  
Glutamate        
Median, g/day 12.8 14.6 15.8 17.0 18.8  
Case: Control Ratio 217:379 237:544 265:525 276:526 227:442  
RR       
Age-adjusted Ref 0.76 0.89 0.91 0.87 0.86 
Model 1 Ref 0.83 0.97 0.99 1.00 0.62 
95% CI2  0.64-1.07 0.75-1.27 0.75-1.31 0.74-1.34  
1Adjusted for age, reference year, age at menarche, body mass index, physical activity, oral contraceptive 
use, parity, smoking status, ever use of antidepressants, childhood trauma, vitamin D from dietary sources 
and total intake of vitamins B6, B1, iron, and zinc at 2-4 years before reference year. 
295% CI is for multivariable model. 
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Table 3.4. Age-adjusted and multivariate relative risks (RR) and 95% confidence 
intervals (CI) for macronutrient (% kcal) substitution models 2-4 years prior to 
diagnosis and risk of premenstrual syndrome (n=3,638); NHS2 PMS Sub-Study, 
1991-2005. 
Substitution Age Adjusted MV11 MV22 
Protein for fat 1.10 (0.97-1.25) 1.04 (0.91-1.19) 0.99 (0.85-1.16) 
Protein for carbohydrate 1.13 (1.01-1.26) 1.12 (0.95-1.31) 1.01 (0.83-1.22) 
Fat for carbohydrate 1.06 (1.00-1.13) 1.06 (0.94-1.20) 1.02 (0.87-1.18) 
Fat for protein 1.05 (0.95-1.17) 0.98 (0.92-1.05) 1.00 (0.92-1.07) 
Carbohydrate for fat 0.97 (0.92-1.02) 1.07 (0.97-1.17) 1.02 (0.90-1.15) 
Carbohydrate for protein 0.99 (0.91-1.07) 1.05 (0.99-1.12) 1.01 (0.94-1.09) 
1MV1= age, reference year, age at menarche, body mass index, physical activity, oral contraceptive use, 
parity, smoking status, ever use of antidepressants, childhood trauma, vitamin D from dietary sources and 
total intake of vitamins B6, B1, and iron. 
2MV2= MV1 + history of depression, and total intake of calcium, vitamins B12 and B2, folate, zinc, and 
potassium. 
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